Home » About

About

Q: Export authorizations include:

All manufactured products. SAHPRA GMP Certificate in terms with Section 22C(1)(b) and SAHPRA GMP guidelines. SAHPRA written confirmation of GMP for APIs for active substances exported into the European union for medicinal products for human use in accordance with Article 46b(2)(b) of Directive 2001/83/EC.

Dedicated biotechnology company providing cannabinoid based therapeutic actives

Welcome to GESLabs

Committed to developing safe and high-quality medicines for patients

By harnessing the power of naturally abundant therapies and incorporating modern scientific discoveries, we are at the forefront of unveiling the vast medical and health-related benefits that cannabinoids offer.

Embark on this journey with us as we lead the way in pioneering research and innovation, establishing ground-breaking benchmarks through the developments of our cannabinoid-based product range.

Our Technology

We take pride in our state-of-the-art active pharmaceutical manufacturing solution, specifically designed and built to standardize our cannabinoid-based therapy applications.

Our technology suite includes GMP active extraction, intermediate API production, and API isolation, providing a full range of manufacturing capabilities.

Our bespoke manufacturing skids are designed to meet the highest global GMP requirements and regulations. By utilizing cryoethanol solutions and inline refinement technologies, we offer end-to-end pant-to-API solutions with maximized outputs and high-quality inputs. Our technologies are engineered for high efficiencies, allowing for cost-effective scalability, thus enabling our customers to achieve their goals.

At our core, we believe that quality is paramount, and we strive to create products that meet the highest standards while delivering optimal patient outcomes.

The Leading Edge

World Class Technology

Pharma Engineering
Team

In-House Research & Development

Global Quality Standards

GMP-Compliant

Why medical cannabis?

Medical cannabis refers to the use of components as a therapy to manage certain ailment-specific conditions and their associated symptoms.

These components of cannabis, specifically CBD and THC have shown to act on the endocannabinoid system within the body and so have been proven to have medicinal properties for certain diseases.

Pharmaceutical preparations of cannabis have been clinically tested and approved for use in the following indications:

Lennox-Gastaut syndrome and Dravet Syndrome
Spasticity associated with multiple sclerosis
Nausea and vomiting associated with chemotherapy
Nausea and appetite loss due to chemotherapy, HIV or AIDS

Our Team

At the heart of our company lies a core team of exceptionally talented and experienced professionals.

We are a group of technically-skilled chemical and process pharmaceutical engineers, analytical chemists, regulatory pharmacists, production pharmacists, packaging/brand specialists, and GMP quality assurance experts who share a common vision of creating world-class medical cannabis API products.

Founded by Peter Nel, we have carved out a unique niche in the industry. We are committed to delivering high-quality API cannabinoids and alkaloids with specific dosage formats that meet the needs of patients worldwide. As a technology provider, our initial focus was on research and development, and model development. Today, we have leveraged our strengths to drive innovation in the cannabinoid and alkaloid manufacturing space.

We are driven by a relentless desire to push the boundaries of what is possible. We thrive on tackling the most challenging problems and delivering solutions that exceed expectations. Our commitment to quality and innovation is unmatched, and we are dedicated to creating products that truly make a difference in the lives of patients. Join us on our journey as we continue to break new ground in the world of medical cannabis.

Certifications

SAHPRA Section 22C(1)(b) of the medicines and related substances Act, 1965 to act as a manufacturer, importer and exporter:

GES holds a South African Products Health Regulatory Authority (SAHPRA) manufacturing authorization (License No: 1401.-.2) that authorises us in accordance to Section 22C(1)(b) of the Medicines and Related substances Act, 1965 (Act 101 of 1965) to import, export, manufacture, pack, label and distribute cannabinoid containing products as well as a GMP certificate (26/7/3/31/1/G0053/2023).

We also hold a written confirmation of GMP for export of active substances into the European Union for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC.

View GESLabs SAHPRA licence here.

Manufacturing authorizations include:

Bulk API containing cannabinoids, including Dronabinol extracted from cultivated cannabis.
Dronabinol formulated extract
THC/CBD formulated extract
CBD Isolate
Dronabinol syringes
THC/CBD cartridges

Packaging authorizations include:

Packaging and labelling of manufactured products
Re-labelling or redressing
Cartoning or secondary packaging

Testing authorizations include:

Analytical testing
Stability

Import authorizations include:

All cannabinoid containing products, except biomass.

Export authorizations include:

All manufactured products.

SAHPRA GMP Certificate in terms with Section 22C(1)(b) and SAHPRA GMP guidelines.

SAHPRA written confirmation of GMP for APIs for active substances exported into the European union for medicinal products for human use in accordance with Article 46b(2)(b) of Directive 2001/83/EC.

Parameters	Specification
Formulation	>98% CBD
Appearance	White crystalline powder
Packaging	1kg HDPE container
Storage	Tightly closed, protected from light, 15 - 25° C
Shelf Life	24-months (stability ongoing)
Extraction	Ethanol
Origin	South Africa
Stability Status	Conducted according to ICH stability guidelines Long term studies up to: 24 months (25°C±2°C, 60% ± 5%RH) Accelerated studies up to: 6 months (40°C±2°C, 75% ± 5%RH)

Parameters	Specification
Formulation	400-440/800-880 mg THC distillate + Chemovar terpene concentration
Appearance	Yellow-gold viscous liquid, solid at room temperature
Packaging	1ml SS316 or All-Ceramic 10-Thread cartridge 0.5ml SS316 or All-Ceramic 10-Thread cartridge
Storage	Tightly closed, protected from light, 15 - 25° C
Shelf Life	12 months
Extraction	Cryo-ethanol extraction Low temperature Decarboxylation to preserve terpenes
Origin	South Africa
Stability Status	Conducted according to ICH stability guidelines Long term studies up to: 12 months (25°C±2°C, 60% ± 5%RH) Accelerated studies up to: 6 months (40°C±2°C, 75% ± 5%RH)

Parameters	Specification
Formulation	400-440/800-880mg THC distillate + Botanical terpene concentration
Appearance	Yellow-gold viscous liquid, solid at room temperature
Packaging	1ml SS316 or All-Ceramic 10-Thread cartridge 0.5ml SS316 or All-Ceramic 10-Thread cartridge
Storage	Tightly closed, protected from light, 15 - 25° C
Shelf Life	12 months
Extraction	Cryo-ethanol extraction Low temperature Decarboxylation to preserve terpenes
Origin	South Africa
Stability Status	Conducted according to ICH stability guidelines Long term studies up to: 12 months (25°C±2°C, 60% ± 5%RH) Accelerated studies up to: 6 months (40°C±2°C, 75% ± 5%RH)

Parameters	Specification
Formulation	400/800mg THC Live Rosin concentration
Appearance	Yellow-gold viscous liquid, solid at room temperature
Packaging	1ml All-Ceramic 510-Thread Cartridge 0.5ml All-Ceramic 510-Thread Cartridge
Storage	Tightly closed, protected from light, 15 - 25° C
Shelf Life	12 months
Extraction	EP-grade water and low temperature pressing, fresh frozen cannabis flower
Origin	South Africa
Stability Status	Conducted according to ICH stability guidelines Long term studies up to: 12 months (25°C±2°C, 60% ± 5%RH) Accelerated studies up to: 6 months (40°C±2°C, 75% ± 5%RH)

Parameters	Specification
Formulation	400/800mg THC Live Resin concentration
Appearance	Yellow-gold viscous liquid, solid at room temperature
Packaging	1ml All-Ceramic 510-Thread Cartridge 0.5ml All-Ceramic 510-Thread Cartridge
Storage	Tightly closed, protected from light, 15 - 25° C
Shelf Life	12 months
Extraction	Low temperature hydrocarbon, fresh frozen cannabis flower
Origin	South Africa
Stability Status	Conducted according to ICH stability guidelines Long term studies up to: 12 months (25°C±2°C, 60% ± 5%RH) Accelerated studies up to: 6 months (40°C±2°C, 75% ± 5%RH)

About

Committed to developing safe and high-quality medicines for patients

Our Technology